Serotonergic psychedelics as epigenetic modulators: A paradigm shift in Alzheimer's disease therapeutics.
Neuroscience and Biobehavioral Reviews May 1, 2026 Esmaeel G Gojani, Houman Farzin, Robert J Sutherland et al.
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by amyloid-β (Aβ) accumulation, tau pathology, synaptic dysfunction, and neuroinflammation, which collectively drive progressive memory loss, cognitive decline, and behavioral changes. Increasing evidence implicates epigenetic dysregulation as a key contributor to these pathological processes by altering gene...